Clinical characteristics of the ALL samples
| . | BCP ALL . | T-ALL . |
|---|---|---|
| Number of patients | 341 | 60 |
| Male/female quotient | 1.21 | 4.0 |
| Median age, y (range) | 4.8 (0.03-17.7) | 9.7 (1.3-17.5) |
| WBC, 109/L* | ||
| Less than 10 | 155 (46%) | 8 (13%) |
| 10 to less than 50 | 119 (35%) | 11 (18%) |
| 50 or more | 62 (18%) | 41 (68%) |
| Missing | 5 (1%) | |
| Cytogenetic abnormality† | ||
| High hyperdiploidy | 104 (30%) | |
| t(12;21) | 73 (21%) | |
| Other clonal abnormality | 55 (16%) | |
| Normal finding | 28 (9%) | |
| MLL/11q23 | 20 (6%) | |
| No result | 18 (5%) | |
| t(1;19) | 16 (5%) | |
| t(9;22) | 11 (3%) | |
| dic(9;20) | 8 (2%) | |
| icamp(21) | 6 (2%) | |
| Hypodiploidy | 2 (0.6%) | |
| Treatment protocol‡ | ||
| NOPHO ALL SR | 91 (27%) | |
| NOPHO ALL IR | 139 (41%) | |
| NOPHO ALL HR | 98 (29%) | 60 (100%) |
| Interfant −99 | 13 (4%) | |
| Events | ||
| Resistant disease | 2 | 4 |
| Induction death | 6 | 4 |
| Death in CCR | 6 | 4 |
| Second malignancy | 5 | 0 |
| Relapse | 69 | 13 |
| CCR | 253 | 35 |
| Median follow-up, mo (range) | 74 (19-153) | 75 (27-154) |
| p-DFS§ (SE) | ||
| 3 y | 0.82 (0.02) | 0.67 (0.06) |
| 5 y | 0.76 (0.03) | 0.67 (0.06) |
| p-OS(SE) | ||
| 3 y | 0.89 (0.02) | 0.62 (0.07) |
| 5 y | 0.85 (0.03) | 0.62 (0.07) |
| . | BCP ALL . | T-ALL . |
|---|---|---|
| Number of patients | 341 | 60 |
| Male/female quotient | 1.21 | 4.0 |
| Median age, y (range) | 4.8 (0.03-17.7) | 9.7 (1.3-17.5) |
| WBC, 109/L* | ||
| Less than 10 | 155 (46%) | 8 (13%) |
| 10 to less than 50 | 119 (35%) | 11 (18%) |
| 50 or more | 62 (18%) | 41 (68%) |
| Missing | 5 (1%) | |
| Cytogenetic abnormality† | ||
| High hyperdiploidy | 104 (30%) | |
| t(12;21) | 73 (21%) | |
| Other clonal abnormality | 55 (16%) | |
| Normal finding | 28 (9%) | |
| MLL/11q23 | 20 (6%) | |
| No result | 18 (5%) | |
| t(1;19) | 16 (5%) | |
| t(9;22) | 11 (3%) | |
| dic(9;20) | 8 (2%) | |
| icamp(21) | 6 (2%) | |
| Hypodiploidy | 2 (0.6%) | |
| Treatment protocol‡ | ||
| NOPHO ALL SR | 91 (27%) | |
| NOPHO ALL IR | 139 (41%) | |
| NOPHO ALL HR | 98 (29%) | 60 (100%) |
| Interfant −99 | 13 (4%) | |
| Events | ||
| Resistant disease | 2 | 4 |
| Induction death | 6 | 4 |
| Death in CCR | 6 | 4 |
| Second malignancy | 5 | 0 |
| Relapse | 69 | 13 |
| CCR | 253 | 35 |
| Median follow-up, mo (range) | 74 (19-153) | 75 (27-154) |
| p-DFS§ (SE) | ||
| 3 y | 0.82 (0.02) | 0.67 (0.06) |
| 5 y | 0.76 (0.03) | 0.67 (0.06) |
| p-OS(SE) | ||
| 3 y | 0.89 (0.02) | 0.62 (0.07) |
| 5 y | 0.85 (0.03) | 0.62 (0.07) |
SR indicates standard risk; IR, intermediate risk; HR, high risk; p-DFS, predicted disease-free survival; and p-OS, predicted overall survival.
White blood cell count at diagnosis (109/L).
The diagnosis was established at a pediatric oncology center by analysis of bone marrow aspirates with respect to morphology, immunophenotype, and cytogenetics of the leukemic cells. Fluorescence in situ hybridization and/or reverse-transcriptase polymerase chain reaction were applied to identify t(12;21), t(1;19), 11q23, dic(9;20)(p11-13;q11), and icamp(21q22). High hyperdiploidy (HeH) was defined as a modal number more than 50 chromosomes. Immunophenotypes were defined according to the European Group for the Immunological Characterization of Leukaemias. Chromosome banding of bone marrow and/or peripheral blood samples were performed using standard methods. The definition and description of clonal abnormalities followed the recommendations of International System for Human Cytogenetic Nomenclature. Karyotypes were centrally reviewed.
The NOPHO ALL 92 and NOPHO ALL 2000 protocols were used, and their risk group classification was very similar.
p-DFS is predicted disease-free survival, defined as time to relapse, death in CCR or second malignancy.